Acalabrutinib for treating chronic lymphocytic leukaemia: Final appraisal document

DRAFT guidance recommends monotherapy, within marketing authorisation, as option for previously treated adults, and also for use in patients with a 17p deletion or TP53 mutation, or if there is no 17p deletion or TP53 mutation, for use where FCR or BR chemo regimen is unsuitable.

Source:

National Institute for Health and Care Excellence